Equity Analyst, LightStream Research

Shifara Samsudeen, ACMA, CGMA

A chartered management accountant with more than 10 years of rich experience in investment research and financial analysis. Worked as an equity analyst for one of the world's largest asset managers with USD2.5trn in AUM covering numerous sectors including chemicals, retail, tech, autos, telco, real-estate and banks, globally. Experienced in fundamental equity research, industry research, commodity studies, forensic accounting, and due diligence reviews.

Equity Analyst

Freee: Our 2021 Conviction Pick Grew 50% in 2QFY06/21 and That Should Continue

Japan Small Cap Growth - Freee or Money Forward?

SciClone Pharmaceutical IPO: Future Prospects for Zadaxin Troubling

M3 3Q Results: Strong Growth in Earnings Driven by Medical and Overseas Businesses

New Horizon Health IPO Valuation: Healthy Valuation

New Horizon Health IPO: Aiming to Become Pioneer in Cancer Screening

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Long-Short Analysis on Japan, Asia and the World

LightStream Research

LightStream conducts quantitatively rigorous and data-driven analysis with a focus on Japan and Asia.

We consistently cover the Tech, Consumer and Industrial sectors, and provide ECM and Events coverage more broadly.

We supplement traditional qualitative insights from company relationships with a robust quantitative foundation that examines as much historical data as is available.
We further refine the accuracy of our insights and calls through the use of alternative data to flesh out current trends, and through a valuation framework that emphasises non-superficial peer group selection and a proper attempt to understand the metrics and changes that have driven security valuations in the past.

Equity Capital Markets

Joinn Laboratories China  Lt / Equity Capital Markets

<p>Joinn Laboratories, a non-clinical CRO (Contract Research Organization) focused on drug safety assessment has filed for a secondary listing to list its shares on the Hong Kong Stock Exchange and plans to raise about US$600m. The company was initially listed on the Shanghai Stock Exchange in August 2017.</p><p>The company is the market leader in China’s non-clinical drug safety assessment services industry and has experienced strong growth in revenue which grew at a CAGR of over 45% during 2017-2019. With the acquisition of Biomere, the company gained a large number of overseas customers which has helped further grow its revenues. China’s drug CRO market also shows strong growth potential with more pharmaceutical companies trying to cut down on their R&amp;D costs through outsourcing their research functions.</p>

Joinn Laboratories, a non-clinical CRO (Contract Research Organization) focused on drug safety assessment has filed for a secondary listing to list its shares on the Hong Kong Stock Exchange and plans to raise about US$600m. The company was initially listed on the Shanghai Stock Exchange in August 2017.The company is the market leader in China’s non-clinical drug safety assessment services industry and has experienced strong growth in revenue which grew at a CAGR of over 45% during 2017-2019. With the acquisition of Biomere, the company gained a large number of overseas customers which has helped further grow its revenues. China’s drug CRO market also shows strong growth potential with more pharmaceutical companies trying to cut down on their R&amp;D costs through outsourcing their research functions.

Joinn Laboratories IPO: Pioneer of Commercial GLP Laboratories in China Shows Promise